Lilly's triple-agonist retatrutide drives up to 18.8% weight loss, over half of patients fall below obesity threshold

At the EASD Annual Meeting in Milan, Eli Lilly presented data on its triple‑agonist retatrutide.

The trial involved participants with obesity and type 2 diabetes and showed weight reductions of up to 18.8% after roughly a year and a half of treatment.

More than half of the patients dropped below the clinical obesity threshold, moving into a lower weight category.

These findings point to retatrutide as a potentially important therapy for obesity and diabetes management, pending further development.